PRPH, US74345W2070

ProPhase Labs stock: Venkatesan reports 5.48% stake

Published on 11/05/2026 at 03:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ProPhase Labs stock is back in focus after Shyam Venkatesan reported a 5.48 percent stake. The filing gives him sole voting power.

Ownership filing puts focus on control

Shyam Venkatesan reported beneficial ownership of 855,101.981 ProPhase Labs shares.
The filing gives him sole voting and dispositive power over the reported position.
ProPhase Labs operates in genomics, diagnostics and consumer health products.

PRPH, US74345W2070, Illustration mit AI erstellt.

Shyam Venkatesan reported a 5.48 percent beneficial stake in ProPhase Labs on October 16, 2026, according to the StockTitan summary of the SEC filing. The filing was accepted by the SEC on October 19.

Venkatesan reported beneficial ownership of 855,101.981 ProPhase Labs common shares. He disclosed sole voting power and sole dispositive power over the full position, while shared voting and dispositive power were reported as zero.

What the filing means for investors

The disclosure identifies a shareholder with a stake above the 5 percent reporting threshold. The filing also states that the shares were not held with the purpose or effect of changing or influencing control of the issuer, other than activities solely connected with a nomination under Section 240.14a-11.

The filing is an ownership disclosure rather than an announcement of a new operating contract, product launch or financing. Investors will therefore focus on any subsequent ownership filings and on ProPhase Labs' progress in its genomics, diagnostic-development and consumer-products businesses.

ProPhase Labs stock is covered on the ProPhase Labs stock topic page.

Healthcare shares remain sensitive to regulatory developments, financing conditions and changes in investor risk appetite; follow the S&P 500 for the broader US market context.

Find more news and analyses on ProPhase Labs stock.